To share insights and best practices from the implementation of ciltacabtagene autoleucel (cilta-cel) therapy for relapsed or refractory multiple myeloma (RRMM) at the University of Kansas Cancer Center.
Approach:
Patient Selection and Risk Assessment: Focus on appropriate patient selection, baseline risk assessment, and pre-infusion optimization.
Monitoring and Management: Implement acute monitoring and management of adverse events, along with longer-term follow-up.
Key Findings:
Cilta-cel has shown a median overall survival of 60.7 months and 33% of patients achieving progression-free survival of ≥5 years.
Real-world patients often differ from trial populations, typically being older with more comorbidities, yet still achieving favorable outcomes.
A robust multidisciplinary infrastructure is essential for managing the demands of CAR-T therapy.
Interpretation:
Limitations:
The study is based on a single-center experience, which may limit generalizability.
Real-world patient populations may present unique challenges not fully captured in clinical trials.
Conclusion:
The insights gained from the implementation of cilta-cel at KUCC can inform best practices for CAR-T therapy in broader clinical settings.
